Clinical trialNCT06015880RecruitingPhase 1Interventional

Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

SponsorNational Cancer Institute (NCI)Enrollment30Diffuse Large B-Cell Lymphoma, Not Otherwise SpecifiedHigh Grade B-Cell LymphomaTransformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma

View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Joseph M Tuscano
City of Hope Comprehensive Cancer Center LAO
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

8 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

City of Hope Comprehensive Cancer Center
Duarte, California, United States
Geoffrey Shouse
Recruiting
University of California Davis Comprehensive Cancer Center
Sacramento, California, United States
Joseph M. Tuscano
Recruiting
Moffitt Cancer Center
Tampa, Florida, United States
Bijal D. Shah
Recruiting
Northwestern University
Chicago, Illinois, United States
Reem Karmali
Recruiting
Wake Forest University Health Sciences
Winston-Salem, North Carolina, United States
Rakhee Vaidya
Recruiting
Case Western Reserve University
Cleveland, Ohio, United States
Changchun Deng
Recruiting
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, United States
Sami Ibrahimi
Recruiting
University of Virginia Cancer Center
Charlottesville, Virginia, United States
Emily Ayers
Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 20 May 2024
Primary completion: 30 Jun 2027
Completion: 30 Jun 2027
Last update posted: 9 Jul 2026
Registered enrollment: 30
Registry id: NCT06015880

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.